SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : GLAXO (GLX)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: tide who wrote (185)7/8/1998 9:13:00 PM
From: Jeff Litwin  Read Replies (2) of 222
 
Wake up everybody!! There will be an article in tomorrow's New England Journal of Medicine showing that GLX's Lamivudine was highly effective in suppressing the adverse effects of Hepatitis B. It recommends Lamivudine as the drug of choice. Hepatitis B is a major problem in Asia and this can be a major market for this product. Hoping that the news media picks this up and that there will be a pop in the price tomorrow.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News